29. (amended) An antibody capable of selectively binding to a modified chemokine [according to claim 11] consisting of amino acids 5 to 73 of SEQ ID NO: 3.

30. A method for monitoring the circulating level of a selected agent characterized by the ability to induce a hematopoietic synergistic factor in a mammal comprising:

contacting a blood sample from the mammal with an antibody according to claim 28 [or 29],

measuring levels of circulating HSF, and

comparing said circulating HSF levels following administration of said agent to circulating HSF levels prior to administration of said agent.

REMARKS

The amendments presented above have been introduced to delete the allowed subject matter in U.S. Serial No. 08/557,142. No new matter has been added.

No new matter has been introduced.

Respectfully submitted,

Linda E. Hall

Attorney for Applicants Registration No. 31,763

SMITHKLINE BEECHAM CORPORATION
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5016
Facsimile (610) 270-5090
N:\LEH\CASES\P50161\CPA1\D1\PREAMEND.DOC